Medicare Part D plan sponsors are paid prospectively during the year, before the full cost of members’ prescription claims is known, within Medicare prescription drug coverage. After the benefit year ends, the program compares those advance payments with actual claims experience and adjusts the result. That adjustment is the annual reconciliation, and it covers several payment streams rather than a single lump sum.
Final enrollment, final risk scores, actual low-income cost-sharing amounts, actual reinsurance amounts, and the plan’s performance against its bid can all change what the sponsor ultimately receives or owes. An amount that looked accurate during the year may not hold once the accounting closes, and a plan that looked profitable in July can owe funds at settlement. For people who pay premiums, the process matters because recurring differences feed back into how a sponsor sets its next bid.
Why Part D pays plans in advance
A Part D plan submits a bid that reflects its expected costs, and the program makes payments during the year based on that bid and related estimates. This funds the plan while it provides coverage, so it does not have to wait until every claim and member record is final.
Those advance payments are provisional. Enrollment changes through the year, member risk scores are finalized later, and actual claim costs can differ from what the bid assumed. Reconciliation converts the provisional accounting into a final one. The original bid stays in place; reconciliation checks each payment stream against the information available after the year ends.
The payment streams that are reconciled
The direct subsidy is recalculated using final enrollment and final risk scores. Those figures drive the amount tied to the plan’s enrolled population and the expected needs of its members, so the subsidy can shift when the final numbers differ from the estimates.
Low-income cost sharing is paid as estimates through the year and then settled against actual amounts. Reinsurance works the same way: advance payments are compared with the plan’s actual reinsurance amounts, and the difference is settled.
Risk corridors operate differently. They share gain or loss between the sponsor and the program when costs land far enough away from the bid. A plan that spends well above or well below its expectation can face a payment change under this mechanism, which exists to address unusually large departures from the bid’s assumptions.
The final figures determine whether a sponsor receives additional funds or owes money back, an issue also considered in an earlier review of what the OIG found wrong with Medicare Part D.
Why timing changes plan decisions
The settlement lands well after the benefit year ends, when the sponsor has already built its coverage and pricing decisions around the bid. That delay complicates reserves because the sponsor has to account for a payment whose final size is not yet known.
It also shapes future bids. A sponsor whose costs repeatedly ran above expectations will bid differently on the next cycle. Reconciliation therefore connects one benefit year to the next: it is a final accounting and a test of whether the plan’s earlier assumptions held.
For members, none of this appears as a separate charge at the pharmacy. The effect is indirect. Payment results flow into the sponsor’s later pricing and coverage decisions, including the premiums set through future bids, a subject covered in KFF’s Medicare research. A plan that repeatedly underestimates its costs has to change its approach rather than repeat the same assumptions.
Reconciliation does not change coverage exclusions
Part D has long carried a statutory exclusion for drugs used for weight loss, which is why many people buying GLP-1 medication pay cash even when their plan covers other prescriptions. Reconciliation settles the financial arrangements between Part D plans and the program. It does not change that exclusion, and the separate coverage rule can still leave a person responsible for the retail cost.
That distinction matters when estimating what a medication will cost. A plan’s general prescription coverage does not mean it will pay for a drug used for weight loss. Coverage, plan payments, and out-of-pocket price are separate questions, even though they affect one another.
For people facing that gap, a guide to buying GLP-1 medication without insurance lays out what the retail and telehealth routes actually run.